CD44 and neoplasm: Consistent with its biological affinity for the CD44 receptor, HA-based CS or PLGA nanocarriers exploited CD44 overexpression, a major driver of CRC stemness and metastasis, to achieve enhanced tumor uptake, robust anti-proliferative activity, and reduced cell migration compared with free apigenin or uncoated NPs [70].